<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18380">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989910</url>
  </required_header>
  <id_info>
    <org_study_id>MSD-MISP-39299</org_study_id>
    <secondary_id>TVGH-IRB-2013-07-030B</secondary_id>
    <nct_id>NCT01989910</nct_id>
  </id_info>
  <brief_title>Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients</brief_title>
  <official_title>An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Efficacy and Safety of Raltegravir-based Versus Efavirenz-based Combination Therapy in Treatment-naïve Patients With HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to compare the efficacy and safety of raltegravir-based versus efavirenz-based
      combination therapy in treatment-naïve patients with HIV-1 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-center, prospective, randomized, open label, parallel study to compare the efficacy
      and safety of raltegravir-based versus efavirenz-based plus optimal nucleoside
      reverse-transcriptase inhibitors(NRTIs) backbone combination therapy in treatment-naïve
      patients with HIV-1 infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of patients who can achieve of less than 20 HIV RNA copies per ml at week 48 of both arms.</measure>
    <time_frame>At week 48 of both arms</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Virological response to achieve HIV RNA copies &lt;20 copies/mL at week 48 of both arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with achievement of less than 400 HIV RNA copies per ml at week 48 for both arms.</measure>
    <time_frame>At week 48 of both arms</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Virological response to achieve HIV RNA copies &lt;400 copies/mL at week 48 of both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in cluster of differentiation 4(CD4) cell counts at week 48 for both arms.</measure>
    <time_frame>At week 48 of both arms.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change from baseline in cluster of differentiation 4(CD4) cell counts at week 48 for both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of treatment failure at week 48 for both arms.</measure>
    <time_frame>At week 48 of both arms</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The proportion of treatment failure, defined as detectable HIV RNA copies copies/mL, at week 48 for both arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400mg oral twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Efavirenz 600mg oral at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir 400mg oral twice daily</description>
    <arm_group_label>Efavirenz</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Efavirenz 600mg oral at bedtime</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Stocrit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are infected with HIV-1

          -  Patients have not yet received any treatment for HIV

          -  Patients with HIV viral RNA exceeds 5000 copies per ml

          -  Ages at least 20 years

        Exclusion Criteria:

          -  Patients with acute or decompensated chronic hepatitis

          -  Patients with chronic hepatitis and serum aminotransferase concentrations are more
             than five times the upper limit of the normal range

          -  Patients with renal insufficiency (need dialysis or have serum creatinine
             concentrations of more than twice the upper limit of the normal range

          -  Patients with any medical disorder that the use of study medications is
             contraindicated

          -  Pregnant or breastfeeding women

          -  Patients who are lack of expectation to maintain assigned study medication during
             study period

          -  Patients who have received therapy with investigational drugs in the previous 3
             months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wing Wai Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wing Wai Wong, MD</last_name>
    <phone>+886-938590783</phone>
    <email>wwwong@vghtpe.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Infectious Diseases, Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wing Wai Wong, MD</last_name>
      <phone>+886-938590783</phone>
      <email>wwwong@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Wing Wai Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009 Sep 5;374(9692):796-806. Epub 2009 Aug 3.</citation>
    <PMID>19647866</PMID>
  </reference>
  <reference>
    <citation>Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.</citation>
    <PMID>20085491</PMID>
  </reference>
  <reference>
    <citation>Young B, Vanig T, Dejesus E, Hawkins T, St Clair M, Yau L, Ha B, Shield Study Team. A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials. 2010 Sep-Oct;11(5):260-9. doi: 10.1310/hct1105-260.</citation>
    <PMID>21126956</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efavirenz</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Combination antiretroviral therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
